Tagged with B

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

Egypt The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies are rushing in under the umbrella of the universal healthcare law, and the role of France in helping Egypt grow.…

Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…

Korea Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach, and his outlook for the company’s future.   Immuno-oncology has revolutionized cancer therapy, but despite the huge success there has…

Korea Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of its candidates getting close to phase II clinical trials and the construction of a new manufacturing facility that will enable…

Global French mid-cap Ipsen has signed an agreement to acquire US-based oncology specialist Epizyme, with its lymphoma drug, Tazverik, for USD 247 million to bolster its growing oncology presence. Ipsen recently announced that the deal with Epizyme’s will focus on Tazverik (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. in…

Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…

Switzerland After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment from Takeda. “Switzerland is a globally recognized hotspot for biopharma companies. As such, it naturally attracts investments. Our role is…

Global David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time since the start of the COVID-19 pandemic. After more than two years, the 2022 BIO International Convention (BIO2022) was back…

Brazil The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a dire diabetes prediction.   Brazil court approves home grown cannabis for medical use (ABC News) A top court in Brazil…

United Kingdom US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion in profit for the firm last year – has announced a new GBP one billion investment into a UK manufacturing…

USA As of July 1st, long-term Merck alumni, Chirfi Guindo, will be returning to the company to lead Human Health Marketing as chief marketing officer for Merck Human Health and will join the Merck Executive Team after almost 5 years at Biogen. Before the parenthesis at Biogen, where he served as…